{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SOC+chemotherapies&page=2",
    "query": {
      "intervention": "SOC chemotherapies",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 182,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SOC+chemotherapies&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SOC+chemotherapies&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T13:15:16.517Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07188532",
      "title": "Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ewing Sarcoma",
        "Round Cell Sarcoma With EWSR1-non-ETS Fusion"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Conventional Radiotherapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Definitive Surgical Resection",
          "type": "PROCEDURE"
        },
        {
          "name": "Dose-escalated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Electronic Health Record Review",
          "type": "OTHER"
        },
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Hypofractionated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 141,
      "start_date": "2025-11-24",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-10-02T13:15:16.517Z",
      "location_count": 2,
      "location_summary": "Phoenix, Arizona • Rochester, Minnesota",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07188532"
    },
    {
      "nct_id": "NCT07079631",
      "title": "A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "BNT314",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pumitamig",
          "type": "DRUG"
        },
        {
          "name": "SoC chemotherapy treatment 1",
          "type": "DRUG"
        },
        {
          "name": "SoC chemotherapy treatment 2",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 482,
      "start_date": "2025-07-18",
      "completion_date": "2032-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-10-02T13:15:16.517Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • Grand Rapids, Michigan • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07079631"
    },
    {
      "nct_id": "NCT03076216",
      "title": "A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With Gemcitabine +/- Nab-paclitaxel.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Unresectable Locally Advanced Pancreatic Carcinoma"
      ],
      "interventions": [
        {
          "name": "OncoSil™",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "OncoSil Medical Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2017-08-01",
      "completion_date": "2020-11-28",
      "has_results": false,
      "last_update_posted_date": "2021-07-13",
      "last_synced_at": "2026-10-02T13:15:16.517Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Tampa, Florida • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03076216"
    },
    {
      "nct_id": "NCT03313778",
      "title": "Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "mRNA-4157",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SoC Treatment",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 161,
      "start_date": "2017-08-14",
      "completion_date": "2027-11-21",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-02T13:15:16.517Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03313778"
    },
    {
      "nct_id": "NCT00642018",
      "title": "A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "LY2181308 sodium",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "18 Years to 75 Years · Male only"
      },
      "enrollment_count": 154,
      "start_date": "2008-03",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2019-04-03",
      "last_synced_at": "2026-10-02T13:15:16.517Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00642018"
    },
    {
      "nct_id": "NCT06824467",
      "title": "A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Sacituzumab tirumotecan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "H1 receptor antagonist",
          "type": "DRUG"
        },
        {
          "name": "H2 receptor antagonist",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen (or equivalent)",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone (or equivalent)",
          "type": "DRUG"
        },
        {
          "name": "Steroid mouthwash (dexamethasone or equivalent)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 770,
      "start_date": "2025-04-09",
      "completion_date": "2032-11-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-02T13:15:16.517Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • San Francisco, California + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06824467"
    },
    {
      "nct_id": "NCT04054908",
      "title": "Gut Microbiome in Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gastrointestinal Microbiome",
        "Neoplasm, Colorectal"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2018-04-13",
      "completion_date": "2022-06-30",
      "has_results": false,
      "last_update_posted_date": "2024-06-14",
      "last_synced_at": "2026-10-02T13:15:16.517Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04054908"
    },
    {
      "nct_id": "NCT05839119",
      "title": "Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Urothelial Carcinoma Bladder",
        "Androgen Receptor Positive"
      ],
      "interventions": [
        {
          "name": "Degarelix",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine/Cisplatin",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Brown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2023-10-02",
      "completion_date": "2025-10-17",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-10-02T13:15:16.517Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05839119"
    },
    {
      "nct_id": "NCT01042379",
      "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Breast Cancer",
        "Breast Tumors",
        "Angiosarcoma",
        "TNBC - Triple-Negative Breast Cancer",
        "HER2-positive Breast Cancer",
        "HER2-negative Breast Cancer",
        "Hormone Receptor Positive Tumor",
        "Hormone Receptor Negative Tumor",
        "Early-stage Breast Cancer",
        "Locally Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Standard Therapy",
          "type": "DRUG"
        },
        {
          "name": "AMG 386 with or without Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "AMG 479 (Ganitumab) plus Metformin",
          "type": "DRUG"
        },
        {
          "name": "MK-2206 with or without Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "AMG 386 and Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "T-DM1 and Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab and Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Ganetespib",
          "type": "DRUG"
        },
        {
          "name": "ABT-888",
          "type": "DRUG"
        },
        {
          "name": "Neratinib",
          "type": "DRUG"
        },
        {
          "name": "PLX3397",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab - 4 cycle",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib plus Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Patritumab and Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab - 8 cycle",
          "type": "DRUG"
        },
        {
          "name": "SGN-LIV1A",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab plus Olaparib",
          "type": "DRUG"
        },
        {
          "name": "SD-101 + Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Tucatinib plus trastuzumab and pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab plus REGN3767",
          "type": "DRUG"
        },
        {
          "name": "Trilaciclib with or without trastuzumab + pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "SYD985 ([vic-]trastuzumab duocarmazine)",
          "type": "DRUG"
        },
        {
          "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Amcenestrant",
          "type": "DRUG"
        },
        {
          "name": "Amcenestrant + Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Amcenestrant + Letrozole",
          "type": "DRUG"
        },
        {
          "name": "ARX788",
          "type": "DRUG"
        },
        {
          "name": "ARX788 + Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "VV1 + Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Datopotamab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Datopotamab deruxtecan + Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Zanidatamab",
          "type": "DRUG"
        },
        {
          "name": "Lasofoxifene",
          "type": "DRUG"
        },
        {
          "name": "Z-endoxifen",
          "type": "DRUG"
        },
        {
          "name": "ARV-471",
          "type": "DRUG"
        },
        {
          "name": "ARV-471 + Letrozole",
          "type": "DRUG"
        },
        {
          "name": "ARV-471 + Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Endoxifen + Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Rilvegostomig + TDXd",
          "type": "DRUG"
        },
        {
          "name": "Dan222 + Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Sarilumab + Cemiplimab + Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "GSK 5733584",
          "type": "DRUG"
        },
        {
          "name": "GSK 5733584 + Dostarlimab",
          "type": "DRUG"
        },
        {
          "name": "Ivonescimab (20mg/kg Q3W)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QuantumLeap Healthcare Collaborative",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5000,
      "start_date": "2010-03-01",
      "completion_date": "2031-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-02T13:15:16.517Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01042379"
    },
    {
      "nct_id": "NCT04099888",
      "title": "PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "Fimaporfin and Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine/Cisplatin chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PCI Biotech AS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2019-05-23",
      "completion_date": "2022-05-06",
      "has_results": true,
      "last_update_posted_date": "2023-09-11",
      "last_synced_at": "2026-10-02T13:15:16.517Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Atlanta, Georgia • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04099888"
    }
  ]
}